

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form 10-Q/A  
January 26, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

Amendment No. 1

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

for the quarterly period ended December 31, 2005

TRANSITION REPORT PURSUANT TO SECTION 13  
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File No. 0-24676

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

MICHIGAN  
(State or other jurisdiction of  
incorporation or organization)

38-2505723  
(IRS Employer  
Identification No.)

1150 ELIJAH MCCOY DRIVE, DETROIT, MICHIGAN 48202

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 10-Q/A

(Address of principal executive offices)

(Zip Code)

TELEPHONE: (313) 871-8400

Registrant's telephone number, including area code

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

Indicate by check mark whether the registrant is a shell company ((as defined in Rule 12b-2 of the Exchange Act).

Yes  No

As of January 20, 2006 the registrant had 26,421,394 shares of common stock issued and outstanding.

---

**CARACO PHARMACEUTICAL LABORATORIES LTD.**  
(A subsidiary of Sun Pharmaceutical Industries Limited)  
**BALANCE SHEETS**

	<b>DECEMBER 31, 2005</b>	<b>MARCH 31, 2005</b>
	<b>UNAUDITED</b>	<b>AUDITED</b>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 8,865,440	\$ 6,627,425
Accounts receivable, net	19,518,008	6,736,778
Inventories	21,338,531	18,467,693
Prepaid expenses and deposits	3,005,040	1,105,618
	<b>52,727,019</b>	<b>32,937,514</b>
<b>Property, plant and equipment</b>		
Land	197,305	197,305
Building and improvements	9,816,175	9,605,888
Equipment	11,798,108	9,701,979
Furniture and fixtures	667,284	589,329
	<b>22,478,872</b>	<b>20,094,501</b>
Total	22,478,872	20,094,501
Less: accumulated depreciation	8,281,353	7,197,422
	<b>14,197,519</b>	<b>12,897,079</b>
<b>Net property, plant &amp; equipment</b>	<b>14,197,519</b>	<b>12,897,079</b>
<b>Total assets</b>	<b>\$ 66,924,538</b>	<b>\$ 45,834,593</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
<b>Current liabilities</b>		
Accounts payable	\$ 2,178,571	\$ 2,577,669
Accounts payable, Sun Pharma	13,819,750	9,639,890
Accrued expenses	2,048,712	1,931,442
	<b>18,047,033</b>	<b>14,149,001</b>
<b>Total current liabilities</b>	<b>18,047,033</b>	<b>14,149,001</b>
<b>Total liabilities</b>	<b>18,047,033</b>	<b>14,149,001</b>
<b>Commitments and contingencies (notes 11 and 12)</b>		
<b>Stockholders equity</b>		
Common stock, no par value, authorized 30,000,000 shares; issued and outstanding shares - 26,396,394 and 26,360,294 shares	44,956,867	44,927,987
Convertible Series B Preferred Stock, no par value, authorized 15,000,000 shares; issued and outstanding - 9,248,000 and 5,984,000 shares	58,747,770	37,700,410
Additional paid in capital	2,718,735	2,718,735
Accumulated deficit	(57,545,867)	(53,661,540)

	<u>DECEMBER 31,</u> <u>2005</u>	<u>MARCH 31,</u> <u>2005</u>
<b>Total stockholders equity</b>	48,877,505	31,685,592
<b>Total liabilities and stockholders equity</b>	<b>\$ 66,924,538</b>	<b>\$ 45,834,593</b>

See accompanying notes

**CARACO PHARMACEUTICAL LABORATORIES, LTD.**  
(A subsidiary of Sun Pharmaceutical Industries Limited)  
**STATEMENTS OF OPERATIONS**

	NINE MONTHS ENDED DECEMBER 31,		THREE MONTHS ENDED DECEMBER 31,	
	2005	2004	2005	2004
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED
<b>Net sales</b>	\$ 58,087,910	\$ 46,779,221	\$ 20,678,978	\$ 16,680,678
Cost of goods sold	29,861,857	19,050,867	10,329,598	7,283,981
<b>Gross profit</b>	28,226,053	27,728,354	10,349,380	9,396,697
Selling, general and administrative expenses	5,701,231	3,994,400	2,133,346	1,700,241
Research and development costs - affiliate (Note 7)	21,047,360	16,568,880	7,137,280	6,217,920
Research and development costs - other	5,512,554	4,920,003	1,848,167	2,016,052
<b>Operating (loss) income</b>	(4,035,092)	2,245,071	(769,413)	(537,516)
<b>Other income (expense)</b>				
Interest expense	0	(225,788)	0	(8,658)
Interest income	108,130	38,301	54,820	5,549
Other income (expense)	42,635	(14,031)	33,637	(4,582)
<b>Other income (expense) - net</b>	150,765	(201,518)	88,457	(7,691)
<b>Net (loss) income</b>	<b>\$ (3,884,327)</b>	<b>\$ 2,043,553</b>	<b>\$ (680,956)</b>	<b>\$ (545,207)</b>
<b>Net (loss) income per common share</b>				
Basic	(0.15)	0.08	(0.03)	(0.02)
Diluted	(0.15)	0.07	(0.03)	(0.02)

See accompanying notes

**CARACO PHARMACEUTICAL LABORATORIES, LTD.**  
(A subsidiary of Sun Pharmaceutical Industries Limited)  
**STATEMENTS OF CASH FLOWS**

	<b>NINE MONTHS ENDED DECEMBER 31, UNAUDITED</b>	
	<b>2005</b>	<b>2004</b>
<b>Cash flows from operating activities</b>		
Net (loss) income	\$ (3,884,327)	\$ 2,043,553
Adjustments to reconcile net (loss) / income to net cash flow from operating activities		
Depreciation	1,083,931	743,345
Capital stock issued or to be issued to affiliate in exchange for product formula	21,047,360	16,568,880
Changes in operating assets and liabilities which provided (used) cash:		
Accounts receivable	(12,781,230)	(1,842,529)
Inventories	(2,870,838)	(4,487,236)
Prepaid expenses and deposits	(1,899,421)	(70,603)
Accounts payable	3,780,761	3,103,479
Accrued expenses and interest	117,269	(263,060)
<b>Net cash provided by operating activities</b>	<b>4,593,506</b>	<b>15,795,829</b>
<b>Cash flows from investing activities</b>		
Purchases of property, plant and equipment	(2,384,371)	(2,695,404)
<b>Net cash used in investing activities</b>	<b>(2,384,371)</b>	<b>(2,695,404)</b>
<b>Cash flows from financing activities</b>		
Proceeds from loans payable to financial institutions	0	10,000,000
Repayments of loans payable to financial institutions	0	(22,375,000)
Proceeds from exercise of stock options	28,880	3,453,946
Repayments of EDC loan	0	(5,967,716)
<b>Net cash provided by (used in) financing activities</b>	<b>28,880</b>	<b>(14,888,770)</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>2,238,015</b>	<b>(1,788,345)</b>
Cash and cash equivalents, beginning of period	6,627,425	4,244,815
<b>Cash and cash equivalents, end of period</b>	<b>\$ 8,865,440</b>	<b>\$ 2,456,470</b>

See accompanying notes



**CARACO PHARMACEUTICAL LABORATORIES, LTD.**  
(A subsidiary of Sun Pharmaceutical Industries Limited)  
**STATEMENT OF STOCKHOLDERS EQUITY**

	PREFERRED STOCK		COMMON STOCK		ADDITIONAL PAID IN CAPITAL	ACCUMULATED DEFICIT	TOTAL STOCKHOLDERS EQUITY
	SHARES	AMOUNT	SHARES	AMOUNT			
Balances at April 1, 2005	5,984,000	\$ 37,700,410	26,360,294	\$ 44,927,987	\$ 2,718,735	\$ (53,661,540)	\$ 31,685,592
Issuances of preferred stock to affiliate in exchange for product technology transfers	3,264,000	21,047,360					21,047,360
Common stock options exercised			36,100	28,880			28,880
Net loss						(3,884,327)	(3,884,327)
Balances at December 31, 2005	9,248,000	\$ 58,747,770	26,396,394	\$ 44,956,867	\$ 2,718,735	\$ (57,545,867)	\$ 48,877,505

See accompanying notes



**CARACO PHARMACEUTICAL LABORATORIES, LTD.**

**FORM 10-Q/A**

**EXPLANATORY NOTE**

This Amendment No. 1 to the Form 10-Q includes minor changes to the Statement of Cash Flows and Statement of Stockholders' Equity.

**PART II OTHER INFORMATION**

**ITEM 6. EXHIBITS**

- 10.26 Credit Agreement dated as of November 17, 2005 between Caraco and JP Morgan Chase Bank, N.A. (Filed with original Form 10-Q)
- 10.27 Security Agreement dated as of November 17, 2005 between Caraco and JP Morgan Chase Bank, N.A. (Filed with original Form 10-Q)
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer.
- 32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CARACO PHARMACEUTICAL  
LABORATORIES, LTD.

Date: January 26, 2006

By: /s/ Daniel H. Movens  
Daniel H. Movens  
Chief Executive Officer

Date: January 26, 2006

By: /s/ Jitendra N. Doshi  
Jitendra N. Doshi  
Chief Financial Officer

EXHIBIT INDEX

<u>31.1</u>	<u>Certificate of Chief Executive Officer</u>
<u>31.2</u>	<u>Certificate of Chief Financial Officer</u>
<u>32.1</u>	<u>Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.</u>